<DOC>
	<DOCNO>NCT01355445</DOCNO>
	<brief_summary>This international open-label , randomize , multicenter phase II study VIT VI treatment patient recurrent refractory rhabdomyosarcoma . The study evaluate safety efficacy combination patient recurrent refractory rhabdomyosarcoma .</brief_summary>
	<brief_title>Vincristine Irinotecan With Without Temozolomide Children Adults With Refractory Relapsed Rhabdomyosarcoma : International Randomized Trial</brief_title>
	<detailed_description>The dose vincristine 1.5 mg/m² 0.05 mg/kg patient ≤ 10 kg ( maximum 2 mg ) administer direct intravenous infusion day 1 8 course , irinotecan . The dose irinotecan 50 mg/m²/d . Irinotecan give intravenously 1 hour day 1-5 course , one hour follow administration temozolomide . In absence contraindication ( ie know allergy ) , treatment oral cefixime 8 mg/kg daily ( maximum daily dose 400 mg ) recommend start 2 day chemotherapy day 7 . Temozolomide give accord randomization . The start dose temozolomide 125 mg/m²/d . The dose temozolomide escalate 150 mg/m²/day cycle 2 patient experience &gt; grade 3 toxicity kind . Temozolomide give orally , empty stomach , day 1 5 course . Dose reduction and/or administration delay perform use specific predefined rule accommodate individual patient tolerance treatment maintain optimal dose intensity .</detailed_description>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>TUMOR CHARACTERISTICS : Histologically cytologically confirm diagnosis rhabdomyosarcoma ( RMS ) ( new biopsy recommend ) Relapsed refractory disease fail standard treatment approach Patients must measurable disease defined lesion measure 3 dimension medical image technique CT MRI . Ascites , pleural fluid , bone marrow disease lesion see Tc scintigraphy PET scan consider measurable patient PATIENT CHARACTERISTICS : Age &gt; 6 month ≤ 50 year Karnofsky performance status ( PS ) 70100 % ( patient &gt; 12 year age ) OR Lansky Play Score 70100 % ( patient ≤ 12 year age ) Life expectancy ≥ 12 week Adequate bone marrow function : Absolute neutrophil count ≥ 1000/mm3 Platelet count ≥ 100,000/mm3 ( transfusion independent ) Hemoglobin ≥ 8.5 g/dl ( transfusion allow ) Adequate renal function Serum creatinine &lt; 1.5 X ULN age If serum creatinine &gt; 1.5 ULN , creatinine clearance ( radioisotope GFR ) must &gt; 70 ml/min/1.73 m² Adequate hepatic function : Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) age , except patient know Gilbert 's syndrome ALT AST &lt; 2.5 time ULN age Negative pregnancy test female childbearing potential Fertile patient must use effective contraception No active &gt; grade 2 diarrhea uncontrolled infection No malignancy , include secondary malignancy Patient affiliate health insurance system . Applicable French patient Written inform consent patient and/or parents/guardians PRIOR CONCURRENT THERAPY : More 3 week since prior radiation therapy site progressive lesion identify target lesion measure tumor response At least 3 week since prior myelosuppressive therapy ( 6 week nitrosourea . 2 week vincristine , vinblastine , vinorelbine low dose cyclophosphamide ) No concurrent enzymeinducing anticonvulsant ( EIAC ) , include phenytoin , phenobarbital carbamazepine No concurrent administration follow : rifampicin , voriconazole , itraconazole , ketoconazole , aprepitant , St John 's Wort No prior irinotecan temozolomide administration Prior vincristine administration allow Concurrent palliative radiation therapy sit allow main measurable target Prior allo autologous SCT allow Inclusion criterion failure Concomitant anticancer treatment Pregnancy breast feeding Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption Neuromuscular disorder ( e.g . CharcotMarie Tooth disease ) Uncontrolled intercurrent illness active infection Unavailable medical followup ( geographic , social psychological reason )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>